Mangoceuticals, Inc. cash flow statement

In fiscal 2025, Mangoceuticals, Inc.'s operations generated −$5.9m of cash; it spent $0 on capital projects, leaving free cash flow of −$5.9m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Mangoceuticals, Inc.: cash flow statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−1,347	−6,997	−4,864	−5,850	−3,891
Depreciation and amortisation	4	25	10	1	1
Stock-based pay	234	624	249	1,168	2,169
Capital spending	43	4	0	0	0
Free cash flow	−1,390	−7,001	−4,864	−5,850	−3,891
Free cash flow after stock pay	−1,624	−7,625	−5,112	−7,019	−6,060
Shares issued	2,000	6,200	1,328	4,625	—

US$ thousands unless shown otherwise. Fiscal quarters.

Mangoceuticals, Inc.: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−1,166	−1,130	−2,275	−1,256	−1,241	−1,078	−1,311	−261
Depreciation and amortisation	3	0	0	0	0	0	0	0
Stock-based pay	109	51	51	51	1,100	−33	1,090	12
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−1,166	−1,130	−2,275	−1,256	−1,241	−1,078	−1,311	−261
Free cash flow after stock pay	−1,275	−1,181	−2,326	−1,307	−2,341	−1,044	−2,401	−273
Shares issued	0	760	655	431	1,325	2,215	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ATPC vs MGRX AHG vs MGRX AMS vs MGRX

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Mangoceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mangoceuticals, Inc.